Insight Molecular Diagnostics Inc. (IMDX): Capital Expenditures
$3.19M
Year ended 2025-12-31
$3.92M
Trailing 12 months to 2026-06-30
-9.8%
3-year compound annual growth
+21.0%
5-year compound annual growth
+20.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.19M | +517.2% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $516.0K | +83.6% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $281.0K | -93.5% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $4.34M | +93.1% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $2.25M | +83.1% | 2023-04-12, From 2021-01-01 |
| 2020-12-31 | $1.23M | +33.7% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $918.0K | n/m | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $31.0K | -65.9% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $91.0K | -14.2% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $106.0K | -78.8% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $500.0K | n/m | 2018-04-02, From 2015-01-01 |
| 2014-12-31 | $9.0K | n/a | 2017-02-27, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $3.19M | +517.2% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $16.0K | -56.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $89.6K | -67.7% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $2.71M | +41.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $1.25M | +168.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $1.15M | +2.0% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $1.13M | -80.5% |
| Neogen Corp (NEOG) | 2026-05-31 | $51.30M | -51.0% |
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $187.3K | -12.8% |
Compare IMDX, AWHL, VNRX, CLDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗